CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB064

Nerve Fiber Density Testing (ENFD) — Skin Biopsy

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLAB064 alerts

Get alerted when Policy CPCPLAB064 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines reimbursement and coverage criteria for epidermal nerve fiber density measurement from skin biopsy to diagnose small-fiber neuropathy for Blue Cross and Blue Shield of Texas members.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyNerve Fiber Density Testing (ENFD) — Skin Biopsy

Policy CodePolicy CPCPLAB064

Change TypeNew policy

Effective DateJan 1, 2025

Last ReviewSep 13, 2024

Next Review Date

Key ActionSubmit supporting clinical documentation showing symptoms of painful sensory neuropathy, absence of predisposing disorders, normal large-fiber exam and normal EMG/nerve conduction studies to demonstrate that all coverage criteria are met.

SourceLink

POLICY UPDATE CHANGES

New policy establishing reimbursement criteria for epidermal nerve fiber density measurement from skin biopsy for diagnosis of small-fiber neuropathy.

1Distinct covered indication

0Sweat gland NFD reimbursable

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB064

Nerve Fiber Density Testing (ENFD) — Skin Biopsy

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLAB064 alerts

Get alerted when Policy CPCPLAB064 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines reimbursement and coverage criteria for epidermal nerve fiber density measurement from skin biopsy to diagnose small-fiber neuropathy for Blue Cross and Blue Shield of Texas members.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyNerve Fiber Density Testing (ENFD) — Skin Biopsy

Policy CodePolicy CPCPLAB064

Change TypeNew policy

Effective DateJan 1, 2025

Last ReviewSep 13, 2024

Next Review Date

SourceLink

POLICY UPDATE CHANGES

New policy establishing reimbursement criteria for epidermal nerve fiber density measurement from skin biopsy for diagnosis of small-fiber neuropathy.

1Distinct covered indication

0Sweat gland NFD reimbursable

Coverage Criteria

Covered indication — initial diagnostic ENFD

Epidermal nerve fiber density (ENFD) measurement from a skin biopsy is reimbursable for diagnosis of small‑fiber neuropathy when ALL of the following are met:

Reimbursable criteria

Clinical presentation: An individual presents with symptoms of painful sensory neuropathy.
Predisposing conditions absent: There is no history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy).
Physical examination shows no evidence of findings consistent with large‑fiber neuropathy (such as reduced or absent muscle‑stretch reflexes or reduced proprioception and vibration sensation).
Electrodiagnostic testing: Electromyography and nerve‑conduction studies are normal and show no evidence of large‑fiber neuropathy.

Coverage note: All listed conditions must be satisfied for reimbursement of ENFD measurement from skin biopsy.

For situations not meeting the listed diagnostic criteria, epidermal nerve fiber density (ENFD) measurement from skin biopsy is not reimbursable. The policy limits reimbursement to the specific clinical scenario described for diagnosis of small-fiber neuropathy; any other use or indication is excluded from coverage.

The policy explicitly states that measurement of sweat gland nerve fiber density is not reimbursable under any circumstance described in this document.

ENFD testing is reimbursable only when all required diagnostic criteria are satisfied. If those criteria are not met, ENFD testing is not reimbursable. Additionally, the policy specifically excludes measurement of sweat gland nerve fiber density from reimbursement.

Coding and Diagnostic Tests

Procedure Codes (listed guidance — no codes specified)mixed

No codes listed

inv-06: Electrodiagnostic testing — EMG and nerve-conduction studies

Electrodiagnostic testing requirementElectromyography (EMG) and nerve-conduction studies must be normal and show no evidence of large-fiber neuropathy.

PurposeDemonstrates absence of large-fiber involvement to support diagnosis of small-fiber neuropathy by ENFD.

Consequences if abnormalIf EMG/nerve conduction studies show large-fiber neuropathy, epidermal nerve fiber density measurement from skin biopsy is not reimbursable under the covered indication.

Provider Actions and Billing

Note

Prior authorization guidance — no explicit PA codes listed

The policy text does not list specific prior authorization procedure codes or state a formal prior authorization requirement for epidermal nerve fiber density (ENFD) testing; providers should follow their plan or contract for any local prior authorization procedures.

Note

Additional provider actions and plan-specific requirements

No additional provider-action notes are specified beyond the requirements for documentation, coding, and the absence of explicit PA codes; follow plan documents and provider contracts for any local requirements.

Documentation Required

Required documentation and coding

Submit supporting clinical documentation that demonstrates all coverage criteria are met and follow plan-specific authorization processes where applicable.

Background

Skin biopsy with measurement of epidermal nerve fiber density (ENFD) is used as a diagnostic tool for small-fiber (painful sensory) neuropathy when clinical presentation and testing do not indicate large-fiber involvement. The policy requires four conditions be met for reimbursement: presence of symptoms of painful sensory neuropathy; no history of a disorder known to predispose to painful neuropathy (for example, diabetic, toxic, HIV, celiac, or inherited neuropathies); physical examination without findings consistent with large-fiber neuropathy (such as preserved muscle-stretch reflexes and intact proprioception and vibration); and normal electromyography and nerve-conduction studies showing no evidence of large-fiber neuropathy.

Definitions

inv-12: ENFD — Epidermal nerve fiber density measurement

DefinitionEpidermal nerve fiber density (ENFD) measurement is a quantitative assessment of small unmyelinated intraepidermal nerve fibers obtained from a skin biopsy.

Primary useDiagnostic test to evaluate for small-fiber neuropathy when clinical criteria are met and large-fiber studies are normal.

Reimbursement contextENFD measurement from skin biopsy may be reimbursable when all policy coverage criteria are satisfied.

inv-13: Small-fiber neuropathy — definition and clinical presentation

DefinitionSmall-fiber neuropathy is a neuropathy affecting small sensory fibers, commonly presenting with painful sensory symptoms while large-fiber exam and electrodiagnostic studies remain normal.

Typical clinical presentation